Physician profile
Patrick J Corcoran
NPI 1144298415
$11,779.52
in general payments reported to CMS, 2019-2025
33 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $1,188 · 2021: $1,417 · 2022: $1,370 · 2023: $2,599 · 2024: $3,794 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434 · Travel and Lodging: $3,188 · Consulting Fee: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.30 |
| Travel and Lodging | $3,187.51 |
| Consulting Fee | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,890.33 | 2019-2024 | Optis, Xience Skypoint, Cardiomems |
| Janssen Pharmaceuticals, INC | $1,246.38 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $692.40 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $611.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $566.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $410.70 | 2019-2023 | Farxiga |
| Amgen INC. | $213.24 | 2019-2021 | |
| Medtronic, INC. | $193.99 | 2022 | |
| Philips North America LLC | $179.80 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $176.13 | 2019-2022 | |
| Amarin Pharma, INC. | $170.29 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.27 | 2019-2022 | |
| Terumo Medical Corporation | $127.78 | 2020 | |
| Medtronic Vascular, INC. | $119.89 | 2019 | |
| Boston Scientific Corporation | $111.72 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $97.86 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.52 | 2022-2024 | Lifevest |
| Shockwave Medical, INC | $82.71 | 2025 | |
| Bard Peripheral Vascular, INC. | $76.41 | 2025 | Fluency Endovascular Stent Graft |
| Novo Nordisk INC | $75.58 | 2021-2025 | Wegovy |
| Bardy Diagnostics, INC. | $74.62 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $69.69 | 2020-2022 | |
| Inari Medical, INC. | $56.79 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $53.45 | 2020-2024 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $50.42 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $46.98 | 2021 | |
| Akcea Therapeutics, INC. | $44.90 | 2019-2021 | |
| Genzyme Corporation | $33.42 | 2019 | |
| Baxter Healthcare | $22.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $18.35 | 2022 | |
| Heartflow, INC. | $16.76 | 2022 | |
| Preventice Services, LLC | $13.41 | 2019 | |
| Cardiovascular Systems INC. | $6.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Corcoran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.